Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid TumorsFLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement ...

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has reached a strategic agreement with LabFlorida/SunDx Labs to provide residents of senior living communities access to Guardant Shieldâ,,g, the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for colorectal cancer (CRC). As part of the agreement, LabFlorida will serve as the exclusive distributor to senior living c. ...

Accessibility StatementSkip Navigation 85% of Gen Z and Millennials Said They Would Use a GenAI Shopping Assistant, with Shoppers Looking for AI to Help Compare Products and Provide Gift Recommendations MONTREAL, LONDON, and NEW YORK, Sept. 11, 2025 /PRNewswire/ - Coveo (TSX: CVO), the leader in AI-Relevance, delivering best-in-class AI-search and generative experiences that maximize business outcomes at every point-of-experience, today announced a new research report titled, "Shoppers Say Yes to GenAI This ...

Jeff Bezos didn’t become one of the world’s richest people by playing it safe. Instead, his approach to risk-taking transformed a garage startup into a global empire, and his strategies can work for everyday financial decisions too. Learn More: Multimillionaire Says Timing the Market Is Impossible – Here’s What You Should Do Instead Read Next: How Much Money Is Needed To Be Considered Middle Class in Your State? Here’s how to think about risk like Bezos, even if your bank account looks nothing like his. ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized sto ...

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York. As a journalist, he has covered every futures market traded in the U.S., at one time or another. Jim is the proprietor of the "Jim Wyckoff on the Markets" analytical, educational and trading advisory service. Jim also worked as a ...

In this articleGS07 July 2025, USA, New York: A street sign reading "Wall Street" hangs on a post in front of the New York Stock Exchange in Manhattan's financial district. Photo: Sven Hoppe/dpa (Photo by Sven Hoppe/picture alliance via Getty Images)Picture Alliance | Picture Alliance | Getty ImagesA version of this article first appeared in CNBC's Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbo ...

Accessibility StatementSkip Navigation ENGLEWOOD, Colo., Sept. 11, 2025 /PRNewswire/ -- EchoStar Corporation (NASDAQ: SATS) will host a meeting to discuss the company's new focus on Monday, September 15, 2025, at 10 a.m. Central European Summer Time at World Space Business Week in Paris. The meeting will be broadcast live and may be accessed on EchoStar's Investor Relations website at https://ir.echostar.com/investors. A replay of the webcast will be available on the Company's Investor Relations website the ...

OPEC made no changes on Thursday to its relatively high global oil demand growth forecasts for this year and next, and said the world economy was maintaining a solid growth trend in the second half of... ...

Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing productsKey Takeaways:The survival benefits for a new gastric cancer drug, bemarituzumab, were weaker than expected in the final analysis of a Phase Three trialThe news unsettled investors, coming after Zai Lab's latest quarterly earnings also missed the markThe "Rule of 10" is a widely accepted yardstick within the biopharma industry for the chances of commercial succes ...